论文部分内容阅读
目的探讨紫杉醇脂质体辅助化疗治疗复发转移性乳腺癌的临床价值。方法将2011年7月至2012年12月纳入研究的92例患者随机分成两组,观察组患者46例,采用紫杉醇脂质体化疗;对照组患者46例,采用紫杉醇化疗。2个疗程后,评估和比较两组患者的近期疗效和不良反应。结果观察组患者单器官转移、≥2个器官转移的化疗总有效率略高于对照组(P>0.05);观察组和对照组患者的过敏反应发生率分别为19.6%和39.1%,观察组患者的过敏反应发生率明显低于对照组(P<0.05)。结论紫杉醇脂质体辅助化疗治疗复发转移性乳腺癌更安全可靠。
Objective To investigate the clinical value of paclitaxel liposome-assisted chemotherapy in the treatment of recurrent metastatic breast cancer. Methods Ninety-two patients enrolled in the study from July 2011 to December 2012 were randomly divided into two groups. 46 patients in the observation group received paclitaxel liposome chemotherapy and 46 patients in the control group received paclitaxel chemotherapy. After 2 courses, evaluate and compare the short-term curative effect and adverse reaction of two groups of patients. Results The total effective rate of single organ metastasis and ≥2 organs metastasis in observation group was slightly higher than that in control group (P> 0.05). The incidence of allergic reactions in observation group and control group were 19.6% and 39.1% respectively. The observation group The incidence of allergic reaction in patients was significantly lower than that in the control group (P <0.05). Conclusions Paclitaxel liposome adjuvant chemotherapy is more safe and reliable in the treatment of recurrent breast cancer.